Cancer Family
Malignant Thoracic Neoplasm
CI-CAN-00000256Explore in graph →
2,773 active trials51 approved drugs626 evidence items
- NCIt
- C3576
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000256Explore in graph →
Clinical trials
11,496 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,526)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05180422 | A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis | withdrawn | Phase 1 / Phase 2 | 0 | Criterium, Inc.INDUSTRY | 1 | Oct 18, 2023 | clinicaltrials |
| NCT04989283 | Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 26, 2023 |
| clinicaltrials |
| NCT05045404 | Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 13, 2023 | clinicaltrials |
| NCT05935774 | OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | University of WashingtonOTHER | 1 | Aug 25, 2023 | clinicaltrials |
| NCT05400577 | Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC | withdrawn | Phase 2 | 0 | Fox Chase Cancer CenterOTHER | 1 | Jul 17, 2023 | clinicaltrials |
| NCT05411679 | EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Ellipses PharmaINDUSTRY | 3 | Jun 12, 2023 | clinicaltrials |
| NCT04699968 | A Trial of SHR-1701 With or Without Famitinib in Patients With Advanced or Metastatic NSCLC | withdrawn | Phase 2 | 0 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | Jun 7, 2023 | clinicaltrials |
| NCT05582031 | Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers(REFIT-MSS) | withdrawn | Phase 2 | 0 | Translational Research in OncologyOTHER | 0 | Jun 7, 2023 | clinicaltrials |
| NCT04625699 | Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment | withdrawn | Phase 2 | 0 | Catherine ShuOTHER | 0 | Jun 6, 2023 | clinicaltrials |
| NCT02607423 | Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery | withdrawn | Phase 2 | 0 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | May 25, 2023 | clinicaltrials |
| NCT05212922 | A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC(YH001) | withdrawn | Phase 2 | 0 | Eucure (Beijing) Biopharma Co., LtdINDUSTRY | 5 | Mar 20, 2023 | clinicaltrials |
| NCT04650490 | SRS Timing With Immune Checkpoint Inhibition in Patients With Untreated Brain Metastases From Non-small Cell Lung Cancer(STICk-IM-NSCLC) | withdrawn | Phase 2 | 0 | Duke UniversityOTHER | 1 | Mar 2, 2023 | clinicaltrials |
| NCT05481775 | Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Nov 21, 2022 | clinicaltrials |
| NCT05022394 | Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | May 27, 2022 | clinicaltrials |
| NCT04841538 | A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Elpiscience Biopharma, Ltd.INDUSTRY | 0 | Apr 29, 2022 | clinicaltrials |
| NCT05234606 | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Silverback TherapeuticsINDUSTRY | 0 | Apr 12, 2022 | clinicaltrials |
| NCT04754815 | Study of Pembrolizumab With Single Agent Chemotherapy in Elderly Patients With Advanced NSCLC(HFHS 21-01) | withdrawn | Phase 2 | 0 | Shirish GadgeelOTHER | 0 | Mar 29, 2022 | clinicaltrials |
| NCT03770299 | An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease(CheckMate 9TN) | withdrawn | Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 0 | Mar 24, 2022 | clinicaltrials |
| NCT02662634 | A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | GU Research Network, LLCOTHER | 1 | Mar 18, 2022 | clinicaltrials |
| NCT04061590 | Pembrolizumab With or Without Chemotherapy Before Surgery in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | University of California, San FranciscoOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT04470674 | Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients | withdrawn | Phase 2 | 0 | Shirish M GadgeelOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT03321760 | SABR for T1-2a N1 NSCLC | withdrawn | Phase 2 | 0 | Indiana UniversityOTHER | 1 | Feb 9, 2022 | clinicaltrials |
| NCT04928950 | Charcoal in Lung Cancer Patients Undergoing TEMLA | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Feb 9, 2022 | clinicaltrials |
| NCT04758949 | FL-101 in Surgically Resectable Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Flame BiosciencesINDUSTRY | 0 | Jan 11, 2022 | clinicaltrials |
| NCT03319316 | Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)(SOLUTION) | withdrawn | Phase 2 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Jan 10, 2022 | clinicaltrials |
| NCT05007769 | Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC(RAN) | withdrawn | Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Nov 5, 2021 | clinicaltrials |
| NCT04262869 | Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Emory UniversityOTHER | 0 | Oct 27, 2021 | clinicaltrials |
| NCT04430933 | A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC | withdrawn | Phase 1 / Phase 2 | 0 | NextCure, Inc.INDUSTRY | 0 | Aug 18, 2021 | clinicaltrials |
| NCT03786419 | A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma | withdrawn | Phase 2 | 0 | Health Pharma Professional ResearchOTHER | 1 | May 13, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT02038699 | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Jazz PharmaceuticalsINDUSTRY | 1 | Apr 30, 2021 | clinicaltrials |
| NCT04543916 | Venetoclax and Irinotecan in Relapsed/Refractory SCLC | withdrawn | Phase 1 / Phase 2 | 0 | Virginia Commonwealth UniversityOTHER | 0 | Mar 3, 2021 | clinicaltrials |
| NCT03901378 | Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma | withdrawn | Phase 2 | 0 | Ochsner Health SystemOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT04460729 | A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Dec 3, 2020 | clinicaltrials |
| NCT03361319 | Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma(N3) | withdrawn | Phase 1 / Phase 2 | 0 | Royal Marsden NHS Foundation TrustOTHER | 0 | Nov 24, 2020 | clinicaltrials |
| NCT04267913 | Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial) | withdrawn | Phase 2 | 0 | SWOG Cancer Research NetworkNETWORK | 0 | Nov 20, 2020 | clinicaltrials |
| NCT04262375 | A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION(DOMINATION) | withdrawn | Phase 2 | 0 | University Health Network, TorontoOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT02109653 | Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC | withdrawn | Phase 2 | 0 | Array Biopharma, now a wholly owned subsidiary of PfizerINDUSTRY | 1 | Nov 13, 2020 | clinicaltrials |
| NCT03699033 | Hypofractionated Radiotherapy With Carboplatin and Paclitaxel in Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Stephanie SmiddyOTHER | 1 | Nov 5, 2020 | clinicaltrials |
| NCT03501056 | Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer | withdrawn | Phase 2 | 0 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03628144 | Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT02831491 | A Study of Ramucirumab (LY3009806) in Combination With Weekly Docetaxel in Participants With Stage IV Non-Small Cell Lung Cancer | withdrawn | Phase 2 | 0 | Eli Lilly and CompanyINDUSTRY | 0 | Jun 9, 2020 | clinicaltrials |
| NCT02713984 | A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Zhi YangOTHER | 1 | Mar 19, 2020 | clinicaltrials |
| NCT03678090 | The Safety and Efficacy of Fibrinolysis in Patients With an Indwelling Pleural Catheter for Multi-loculated Malignant Pleural Effusion. | withdrawn | Phase 2 | 0 | Yale UniversityOTHER | 0 | Mar 5, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Oct 18, 2023source: clinicaltrials